Larry Alphs, MD, PhD | Psychiatrist.com

Article

Consensus Recommendations for Assessing Suicidal Ideation and Behavior

June 28, 2017

Industry experts gathered to develop guidance for standardized data collection and analysis of suicidal ideation and to guide the development of novel treatments in an effort to rectify the...

Phillip B. Chappell, Michelle Stewart, Larry Alphs, et al

Original Research

The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia

June 24, 2015

Peter J. Weiden, Rebecca S. Roma, Dawn I. Velligan, et al

Original Research

Antipsychotic Therapy in Schizophrenia

April 14, 2015

Read a study discussing Real-World Outcomes of Paliperidone Palmitate compared to Daily Oral Antipsychotic Therapy in Schizophrenia.

Larry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, et al

Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

Dong-Jing Fu, Ibrahim Turkoz, R. Bruce Simonson, et al

Original Research

Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment #01#

October 28, 2014

Larry Alphs, Lian Mao, Stephen C. Rodriguez, et al

Letter to the Editor

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

October 15, 2012

Larry Alphs, William H. Olson, Ibrahim Turkoz, et al